Exelixis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Exelixis (Alameda, CA): 2 reconciled FDA prescription therapies (99.7% 2025 to 2030 cliff risk), $1.35B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Alameda, CA |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 99.7% |
| Primary Portfolio LOE Date | 2032-01-01 |
| 2024 CMS Total Public Spend | $1.35B |
| 2024 Medicare Part D Spend | $1.22B |
| 2024 Medicaid Spend | $129.4M |
| California HCAI SB 17 Filings | 3 WAC filings (max 18.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.